![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-desktop-header-w24-1gif-62145.gif)
![Metrochem API Private Limited](https://www.pharmacompass.com/image/flap/metrochem-mobgif-80388.gif)
Active Filter(s):
Details:
A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.
Lead Product(s): A197
Therapeutic Area: Ophthalmology Product Name: A197
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Dompe Farmaceutici
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Proceeds from the financing will be used to advance the company’s pipeline, including its lead product A197, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment of dry eye disease.
Lead Product(s): A197
Therapeutic Area: Ophthalmology Product Name: A197
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Safar Partners
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 15, 2021